Abstract
Regulation of gene expression is mediated by several mechanisms such as DNA methylation, ATP-dependent chromatin remodeling, and post-translational modifications of histones. The latter mechanism includes dynamic acetylation and deacetylation of η- amino groups of lysine residues present in the tail of the core histones. Enzymes responsible for the reversible acetylation/deacetylation processes are histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. There are three mammalian HDAC families, namely HDACs I, II and III based on their sequence homology. Inhibitors of HDACs induce hyperacetylation of histones that modulate chromatin structure and gene expression resulting in growth arrest, cell differentiation, and apoptosis of tumor cells. In addition, HDAC inhibitors enhance efficacy of anticancer agents that target DNA. Several formidable challenges associated with their development include non-specific toxicity and poor PK properties, including cell permeability. In this review, we comment on the current progress in design, discovery, in vitro/ex vivo activity and clinical potential of the synthetic modulators of HDACs.
Keywords: HDAC, Histone, inhibitors, cancer, QSAR, pharmacophore, docking, bioisoster
Anti-Cancer Agents in Medicinal Chemistry
Title: Histone Deacetylase Inhibitors in Cancer Therapy: Latest Developments, Trends and Medicinal Chemistry Perspective
Volume: 7 Issue: 5
Author(s): Konstantin V. Balakin, Yan A. Ivanenkov, Alex S. Kiselyov and Sergey E. Tkachenko
Affiliation:
Keywords: HDAC, Histone, inhibitors, cancer, QSAR, pharmacophore, docking, bioisoster
Abstract: Regulation of gene expression is mediated by several mechanisms such as DNA methylation, ATP-dependent chromatin remodeling, and post-translational modifications of histones. The latter mechanism includes dynamic acetylation and deacetylation of η- amino groups of lysine residues present in the tail of the core histones. Enzymes responsible for the reversible acetylation/deacetylation processes are histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. There are three mammalian HDAC families, namely HDACs I, II and III based on their sequence homology. Inhibitors of HDACs induce hyperacetylation of histones that modulate chromatin structure and gene expression resulting in growth arrest, cell differentiation, and apoptosis of tumor cells. In addition, HDAC inhibitors enhance efficacy of anticancer agents that target DNA. Several formidable challenges associated with their development include non-specific toxicity and poor PK properties, including cell permeability. In this review, we comment on the current progress in design, discovery, in vitro/ex vivo activity and clinical potential of the synthetic modulators of HDACs.
Export Options
About this article
Cite this article as:
Balakin V. Konstantin, Ivanenkov A. Yan, Kiselyov S. Alex and Tkachenko E. Sergey, Histone Deacetylase Inhibitors in Cancer Therapy: Latest Developments, Trends and Medicinal Chemistry Perspective, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (5) . https://dx.doi.org/10.2174/187152007781668698
DOI https://dx.doi.org/10.2174/187152007781668698 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Emerging Role of Histology in the Choice of First-Line Treatment of Advanced Non-Small Cell Lung Cancer: Implication in the Clinical Decision-Making
Current Medicinal Chemistry Reduced NGF Secretion by HT-29 Human Colon Cancer Cells Treated with a GRPR Antagonist
Protein & Peptide Letters A Review on Antiproliferative and Apoptotic Activities of Natural Honey
Anti-Cancer Agents in Medicinal Chemistry Arginine Deprivation as a Targeted Therapy for Cancer
Current Pharmaceutical Design Anticancer Activity of Ferrocenylthiosemicarbazones
Anti-Cancer Agents in Medicinal Chemistry Prognostic Impact of Tissue Inhibitor of Metalloproteinase-1 in Non- Small Cell Lung Cancer: Systematic Review and Meta-Analysis
Current Medicinal Chemistry Multidrug Resistance Phenotype Mediated by the P-Glycoprotein-Like Transporter in Leishmania: A Search for Reversal Agents
Current Drug Targets Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy 13C Metabolic Flux Analysis: From the Principle to Recent Applications
Current Bioinformatics Compounds Derived from Epigallocatechin-3-Gallate (EGCG) as a Novel Approach to the Prevention of Viral Infections
Inflammation & Allergy - Drug Targets (Discontinued) Book Review
Current Cancer Drug Targets The C-Terminal Half of Heat Shock Protein 90 Represents a Second Site for Pharmacologic Intervention in Chaperone Function
Current Cancer Drug Targets The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab
Recent Patents on Biotechnology Efficient Gene Selection for Cancer Prognostic Biomarkers Using Swarm Optimization and Survival Analysis
Current Bioinformatics Idiopathic Pulmonary Fibrosis: Treatment Strategies
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Aldo-Keto Reductase Family 1 Member B1 Inhibitors: Old Drugs with New Perspectives
Recent Patents on Anti-Cancer Drug Discovery Isolation and Boactivities of Furfuran Type Lignan Compounds from Edible Plants
Recent Patents on Food, Nutrition & Agriculture Inspection and Remedy of Cervical Cancer Using Nanoparticles
Nanoscience & Nanotechnology-Asia Radiological Screening Programs for Women at High Risk of Developing Breast Cancer
Current Women`s Health Reviews Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues
Current Medicinal Chemistry